Web Results

en.wikipedia.org/wiki/GlaxoSmithKline

GlaxoSmithKline plc (GSK) is a British pharmaceutical company headquartered in Brentford, London. Established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, GSK was the world's sixth largest pharmaceutical company as of 2015, after Pfizer, Novartis, Merck, Hoffmann-La Roche and Sanofi.

us.gsk.com

GSK - our mission is to help people do more, feel better, and live longer.

www.gsk.com

The homepage of the GSK global corporate website.

us.gsk.com/en-us/contact-us/our-us-locations

Our global headquarters are in the UK, but we also have a significant presence in the US.

www.bloomberg.com/research/stocks/private/snapshot.asp?privcapId=24082353

GlaxoSmithKline LLC researches, develops, and produces pharmaceuticals, vaccines, and consumer healthcare products. It offers pediatric, adolescent, adult, and travel vaccines; medicines to treat acute and chronic diseases, respiratory diseases, and HIV; over-the-counter medicines; and wellness, oral health, nutrition, ...

www.hoovers.com/company-information/cs/company-profile.glaxosmithkline_llc.e3ede6fdab4cd79e.html

Glaxosmithkline LLC company profile from Hoover's – get an in-depth analysis of Glaxosmithkline LLC business, financials, industry focus, competitors and more.

www.linkedin.com/company/glaxosmithkline

Learn about working at GSK. Join LinkedIn today for free. See who you know at GSK, leverage your professional network, and get hired.

www.moodys.com/credit-ratings/GlaxoSmithKline-LLC-credit-rating-525600

Results 1 - 17 of 17 ... Moody's Investors Service. 18 Jul 2001, Rating Action. MOODY'S WITHDRAWS THE PRIME-1 RATING FOR THE CANCELLED CP PROGRAMMES OF GLAXOSMITHKLINE PLC'S SUBSIDIARIES SMITHKLINE BEECHAM CORP. AND SMITHKLINE BEECHAM (AUSTRALIA) PTY LTD: Moody's Investors ...

www.federalregister.gov/documents/2013/10/23/2013-24840/glaxosmithkline-llc-withdrawal-of-approval-of-the-indication-for-treatment-of-patients-with-relapsed

Oct 23, 2013 ... The Food and Drug Administration (FDA) is withdrawing approval of the indication for treatment of patients with relapsed or refractory, low grade, follicular , or transformed CD20 positive non- Hodgkin's lymphoma who have not received prior rituximab, for BEXXAR (tositumomab and iodine I 131...